Amniotic fluid embolism: Update and review

Current Opinion in Anaesthesiology

Volumn 29, Issue 3, 2016, Pages 288-296

  Sultan, Pervez ^a   Seligman, Katherine ^b   Carvalho, Brendan ^b  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Amniotic fluid embolism; Anaphylactoid; Pregnancy

Indexed keywords

BIOLOGICAL MARKER;

AMNION FLUID EMBOLISM; BLOOD; BLOOD CLOTTING DISORDER; COMPLEMENT ACTIVATION; FEMALE; HUMAN; IMMUNOLOGY; INCIDENCE; PREGNANCY; PROCEDURES; RESUSCITATION; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

BIOMARKERS; BLOOD COAGULATION DISORDERS; CARDIOPULMONARY RESUSCITATION; COMPLEMENT ACTIVATION; EMBOLISM, AMNIOTIC FLUID; FEMALE; HUMANS; INCIDENCE; PREGNANCY; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 84973102466     PISSN: 09527907     EISSN: 14736500     Source Type: Journal    
DOI: 10.1097/ACO.0000000000000328     Document Type: Review

References (90)

1. Clark SL, Hankins GD, Dudley DA, et al. Amniotic fluid embolism: analysis of the national registry. Am J Obstet Gynecol 1995; 172:1158-1167; discussion 67-9.
2. Kramer MS, Rouleau J, Liu S, et al. Maternal Health Study Group of the Canadian Perinatal Surveillance S Amniotic fluid embolism: incidence, risk factors, and impact on perinatal outcome. BJOG 2012; 119:874-879.
3. Clark SL. Amniotic fluid embolism. Obstet Gynecol 2014; 123:337-348.
4. Fitzpatrick K, Tuffnell D, Kurinczuk J, Knight M. Incidence, risk factors, management and outcomes of amniotic-fluid embolism: a population-based cohort and nested case-control study. BJOG 2016; 123:100-109.
5. Knight M, Tuffnell D, Brocklehurst P, et al. System UKOS incidence and risk factors for amniotic-fluid embolism. Obstet Gynecol 2010; 115:910-917.
6. Knight M, Berg C, Brocklehurst P, et al. Amniotic fluid embolism incidence, risk factors and outcomes: a review and recommendations. BMC Pregnancy Childbirth 2012; 12:7.
7. Conde-Agudelo A, Romero R. Amniotic fluid embolism: an evidence-based review. Am J Obstet Gynecol 2009; 201:445e1-445e13.
8. Gilbert WM, Danielsen B. Amniotic fluid embolism: decreased mortality in a population-based study. Obstet Gynecol 1999; 93:973-977.
9. Kramer MS, Rouleau J, Baskett TF, Joseph KS. Maternal Health Study Group of the Canadian Perinatal Surveillance S amniotic-fluid embolism and medical induction of labour: a retrospective, population-based cohort study. Lancet 2006; 368:1444-1448.
10. Abenhaim HA, Azoulay L, Kramer MS, Leduc L. Incidence and risk factors of amniotic fluid embolisms: a population-based study on 3 million births in the United States. Am J Obstet Gynecol 2008; 199:49e1-49e8.
11. Samuelsson E, Hellgren M, Hogberg U. Pregnancy-related deaths due to pulmonary embolism in Sweden. Acta Obstet Gynecol Scand 2007; 86:435-443.
12. Pallasmaa N, Ekblad U, Gissler M. Severe maternal morbidity and the mode of delivery. Acta Obstet Gynecol Scand 2008; 87:662-668.
13. Knight M. Ukoss amniotic fluid embolism: active surveillance versus retrospective database review. Am J Obstet Gynecol 2008; 199:e9.
14. Roberts CL, Algert CS, Knight M, Morris JM. Amniotic fluid embolism in an Australian population-based cohort. BJOG 2010; 117:1417-1421.
15. Hogberg U, Joelsson I. Amniotic fluid embolism in Sweden, 1951-1980. Gynecol Obstet Invest 1985; 20:130-137.
16. Kanayama N, Tamura N. Amniotic fluid embolism: pathophysiology and new strategies for management. J Obstet Gynaecol Res 2014; 40:1507-1517.
17. Kramer MS, Abenhaim H, Dahhou M, et al. Incidence, risk factors, and consequences of amniotic fluid embolism. Paediatr Perinat Epidemiol 2013; 27:436-441.
18. Spiliopoulos M, Puri I, Jain NJ, et al. Amniotic fluid embolism-risk factors, maternal and neonatal outcomes. J Matern Fetal Neonatal Med 2009; 22:439-444.
19. Ito F, Akasaka J, Koike N, et al. Incidence, diagnosis and pathophysiology of amniotic fluid embolism. J Obstet Gynaecol 2014; 34:580-584.
20. Wernet A, Luton D, Muller F, Ducarme G. Use of insulin-like growth factor binding protein-1 for retrospective diagnosis of amniotic fluid embolism in first trimester. Arch Gynecol Obstet 2014; 289:461-462.
21. Moore J, Baldisseri MR. Amniotic fluid embolism. Crit Care Med 2005; 33:S279-S285.
22. Thomas J, Paranjothy S. Royal College of Obstetricians and Gynaecologists Clinical Effectiveness Support Unit. In: National Sentinel Caesarean Section Audit Report. London: RCOG Press; 2001.
23. Office for National Statistics. Birth statistics: Births and patterns of family building England and Wales (FM1). Newport: National Statistics 2007.
24. Frati P, Foldes-Papp Z, Zaami S, Busardo FP. Amniotic fluid embolism: what level of scientific evidence can be drawn? A systematic review. Curr Pharm Biotechnol 2014; 14:1157-1162.
25. Main EK, McCain CL, Morton CH, et al. Pregnancy-related mortality in California: causes, characteristics, and improvement opportunities. Obstet Gynecol 2015; 125:938-947.
26. Oi H, Naruse K, Noguchi T, et al. Fatal factors of clinical manifestations and laboratory testing in patients with amniotic fluid embolism. Gynecol Obstet Invest 2010; 70:138-144.
27. Thomson AJ, Greer IA. Nonhaemorrhagic obstetric shock. Baillieres Best Pract Res Clin Obstet Gynaecol 2000; 14:19-41.
28. Balinger KJ, Chu Lam MT, Hon HH, et al. Amniotic fluid embolism: despite progress, challenges remain. Curr Opin Obstet Gynecol 2015; 27:398-405.
29. Berg CJ, Callaghan WM, Syverson C, Henderson Z. Pregnancy-related mortality in the United States, 1998 to 2005. Obstet Gynecol 2010; 116:1302-1309.
30. Busardo FP, Frati P, Karch SB, Fineschi V. Epidemiological and clinical data of amniotic fluid embolism in forensic settings. Curr Pharm Biotechnol 2014; 14:1189-1194.
31. Benson MD. Current concepts of immunology and diagnosis in amniotic fluid embolism. Clin Dev Immunol 2012; 2012:946576.
32. Tuffnell DJ. United kingdom amniotic fluid embolism register. BJOG 2005; 112:1625-1629.
33. McDonnell NJ, Percival V, Paech MJ. Amniotic fluid embolism: a leading cause of maternal death yet still a medical conundrum. Int J Obstet Anesth 2013; 22:329-336.
34. Kobayashi H. Amniotic fluid embolism: anaphylactic reactions with idiosyncratic adverse response. Obstet Gynecol Surv 2015; 70:511-517.
35. Meyer JR. Embolia pulmonar amnio caseosa. Brasil-Medico 1926; 2:301-303.
36. Steiner PE, Lushbaugh CC. Landmark article, Oct. 1941: Maternal pulmonary embolism by amniotic fluid as a cause of obstetric shock and unexpected deaths in obstetrics. By Paul E. Steiner and C. C. Lushbaugh. JAMA 1986; 255:2187-2203.
37. Rudra A, Chatterjee S, Sengupta S, et al. Amniotic fluid embolism. Indian J Crit Care Med 2009; 13:129-135.
38. Stolte L, van Kessel H, Seelen J, et al. Failure to produce the syndrome of amniotic fluid embolism by infusion of amniotic fluid and meconium into monkeys. Am J Obstet Gynecol 1967; 98:694-697.
39. Benson MD. A hypothesis regarding complement activation and amniotic fluid embolism. Med Hypotheses 2007; 68:1019-1025.
40. Fineschi V, Riezzo I, Cantatore S, et al. Complement C3a expression and tryptase degranulation as promising histopathological tests for diagnosing fatal amniotic fluid embolism. Virchows Arch 2009; 454:283-290.
41. Nishio H, Matsui K, Miyazaki T, et al. A fatal case of amniotic fluid embolism with elevation of serum mast cell tryptase. Forensic Sci Int 2002; 126:53-56.
42. Busardo FP, Frati P, Zaami S, Fineschi V. Amniotic fluid embolism patho-physiology suggests the new diagnostic armamentarium: beta-tryptase and complement fractions C3-C4 are the indispensable working tools. Int J Mol Sci 2015; 16:6557-6570.
43. Farrar SC, Gherman RB. Serum tryptase analysis in a woman with amniotic fluid embolism: a case report. J Reprod Med 2001; 46:926-928.
44. Horn KD, Halsey JF, Zumwalt RE. Utilization of serum tryptase and immu-noglobulin e assay in the postmortem diagnosis of anaphylaxis. Am J Forensic Med Pathol 2004; 25:37-43.
45. Jacob HS, Hammerschmidt DH. Tissue damage caused by activated complement and granulocytes in shock lung, post perfusion lung, and after amniotic fluid embolism: ramifications for therapy. Ann Chir Gynaecol Suppl 1982; 196:3-9.
46. Vercellotti GM, Hammerschmidt DE, Craddock PR, Jacob HS. Activation of plasma complement by perfluorocarbon artificial blood: probable mechanism of adverse pulmonary reactions in treated patients and rationale for corticos-teroids prophylaxis. Blood 1982; 59:1299-1304.
47. Erdei A, Andrasfalvy M, Peterfy H, et al. Regulation of mast cell activation by complement-derived peptides. Immunol Lett 2004; 92:39-42.
48. Luskin AT, Luskin SS. Anaphylaxis and anaphylactoid reactions: diagnosis and management. Am J Ther 1996; 3:515-520.
49. Benson MD, Kobayashi H, Silver RK, et al. Immunologic studies in presumed amniotic fluid embolism. Obstet Gynecol 2001; 97:510-514.
50. Oi H, Kobayashi H, Hirashima Y, et al. Serological and immunohistochemical diagnosis of amniotic fluid embolism. Semin Thromb Hemost 1998; 24:479-484.
51. Kobayashi H, Ohi H, Terao T. A simple, noninvasive, sensitive method for diagnosis of amniotic fluid embolism by monoclonal antibody TKH-2 that recognizes NeuAc alpha 2-6GalNAc. Am J Obstet Gynecol 1993; 168:848-853.
52. Toro K, Borka K, Kardos M, et al. Expression and function of C5a receptor in a fatal anaphylaxis after honey bee sting. J Forensic Sci 2011; 56:526-528.
53. Hikiji W, Tamura N, Shigeta A, et al. Fatal amniotic fluid embolism with typical pathohistological, histochemical and clinical features. Forensic Sci Int 2013; 226:e16-e19.
54. Tamura N, Kimura S, Farhana M, et al. C1 esterase inhibitor activity in amniotic fluid embolism. Crit Care Med 2014; 42:1392-1396.
55. Florio P, Lambert-Messerlian G, Severi FM, et al. Fetal neural tube defects: maternal serum and amniotic fluid activin A levels. Prenat Diagn 2004; 24:574-575.
56. de Lemos JA, Morrow DA. Brain natriuretic peptide measurement in acute coronary syndromes: ready for clinical application? Circulation 2002; 106:2868-2870.
57. Lev-Sagie A, Bar-Oz B, Salpeter L, et al. Plasma concentrations of N-terminal Pro-B-Type natriuretic peptide in pregnant women near labor and during early puerperium. Clin Chem 2005; 51:1909-1910.
58. Takeshima N, Suminami Y, Takeda O, et al.Origin of CA125 and SCC antigen in human amniotic fluid. Asia Oceania J Obstet Gynaecol 1993; 19:199-204.
59. Sarandakou A, Kontoravdis A, Kontogeorgi Z, Rizos D. Phocas I Expression of CEA, CA-125 and SCC antigen by biological fluids associated with pregnancy. Eur J Obstet Gynecol Reprod Biol 1992; 44:215-220.
60. Syversen U, Opsjon SL, Stridsberg M, et al. Chromogranin A and pancreast-atin-like immunoreactivity in normal pregnancies. J Clin Endocrinol Metab 1996; 81:4470-4475.
61. Khong TY. Expression of endothelin-1 in amniotic fluid embolism and possible pathophysiological mechanism. Br J Obstet Gynaecol 1998; 105:802-804.
62. Kuhlman K, Hidvegi D, Tamura RK, Depp R. Is amniotic fluid material in the central circulation of peripartum patients pathologic? Am J Perinatol 1985; 2:295-299.
63. Khosravi J, Krishna RG, Bodani U, et al. Immunoassay of serine-phosphory-lated isoform of insulin-like growth factor (IGF) binding protein (IGFBP)-1. Clin Biochem 2007; 40:86-93.
64. Smulian JC, Vintzileos AM, Lai YL, et al. Maternal chorioamnionitis and umbilical vein interleukin-6 levels for identifying early neonatal sepsis. J Matern Fetal Med 1999; 8:88-94.
65. Kauppila S, Tekay A, Risteli L, et al. Type I and type III procollagen propeptides in amniotic fluid of normal pregnancies and in a case of mild osteogenesis imperfecta. Eur J Clin Invest 1998; 28:831-837.
66. Mock P, Frydman R, Bellet D, et al. Expression of pro-EPIL peptides encoded by the insulin-like 4 (INSL4) gene in chromosomally abnormal pregnancies. J Clin Endocrinol Metab 2000; 85:3941-3944.
67. Raffin-Sanson ML, Ferre F, Coste J, et al. Pro-opiomelanocortin in human pregnancy: evolution of maternal plasma levels, concentrations in cord blood, amniotic fluid and at the feto-maternal interface. Eur J Endocrinol 2000; 142:53-59.
68. Sarandakou A, Protonotariou E, Rizos D. Tumor markers in biological fluids associated with pregnancy. Crit Rev Clin Lab Sci 2007; 44:151-178.
69. Kanayama N, Yamazaki T, Naruse H, et al. Determining zinc coproporphyrin in maternal plasma- A new method for diagnosing amniotic fluid embolism. Clin Chem 1992; 38:526-529.
70. Usta IM, Sibai BM, Mercer BM, et al. Use of maternal plasma level of zinc-coproporphyrin in the prediction of intrauterine passage of meconium: a pilot study. J Matern Fetal Med 2000; 9:201-203.
71. Gist RS, Stafford IP, Leibowitz AB, Beilin Y. Amniotic fluid embolism. Anesth Analg 2009; 108:1599-1602.
72. McDonnell NJ, Chan BO, Frengley RW. Rapid reversal of critical haemody-namic compromise with nitric oxide in a parturient with amniotic fluid embolism. Int J Obstet Anesth 2007; 16:269-273.
73. Stanten RD, Iverson LI, Daugharty TM, et al. Amniotic fluid embolism causing catastrophic pulmonary vasoconstriction: diagnosis by transesophageal echocardiogram and treatment by cardiopulmonary bypass. Obstet Gynecol 2003; 102:496-498.
74. Harnett MJ, Hepner DL, Datta S, Kodali BS. Effect of amniotic fluid on coagulation and platelet function in pregnancy: an evaluation using throm-boelastography. Anaesthesia 2005; 60:1068-1072.
75. Collins NF, Bloor M, McDonnell NJ. Hyperfibrinolysis diagnosed by rotational thromboelastometry in a case of suspected amniotic fluid embolism. Int J Obstet Anesth 2013; 22:71-76.
76. O'Shea A, Eappen S. Amniotic fluid embolism. Int Anesthesiol Clin 2007; 45:17-28.
77. Jeejeebhoy FM, Zelop CM, Lipman S, et al. Cardiac arrest in pregnancy: a scientific statement from the American heart association. Circulation 2015; 132:1747-1773.
78. Lipman S, Cohen S, Einav S, et al. The Society for Obstetric Anesthesia and Perinatology consensus statement on the management of cardiac arrest in pregnancy. Anesth Analg 2014; 118:1003-1016.
79. Burtelow M, Riley E, Druzin M, et al. How we treat: management of life-threatening primary postpartum hemorrhage with a standardized massive transfusion protocol. Transfusion 2007; 47:1564-1572.
80. Collis RE, Collins PW. Haemostatic management of obstetric haemorrhage. Anaesthesia 2015; 70 (Suppl 1):78-86; e27-8.
81. Novikova N, Hofmeyr GJ, Cluver C. Tranexamic acid for preventing post-partum haemorrhage. Cochrane Database Syst Rev 2015; 6:CD007872.
82. Leighton BL, Wall MH, Lockhart EM, et al. Use of recombinant factor VIIa in patients with amniotic fluid embolism: a systematic review of case reports. Anesthesiology 2011; 115:1201-1208.
83. Goldszmidt E, Davies S. Two cases of hemorrhage secondary to amniotic fluid embolus managed with uterine artery embolization. Can J Anaesth 2003; 50:917-921.
84. Sharma NS, Wille KM, Bellot SC, Diaz-Guzman E. Modern use of extracorporeal life support in pregnancy and postpartum. ASAIO J 2015; 61:110-114.
85. Ho CH, Chen KB, Liu SK, et al. Early application of extracorporeal membrane oxygenation in a patient with amniotic fluid embolism. Acta Anaesthesiol Taiwan 2009; 47:99-102.
86. Hsieh YY, Chang CC, Li PC, et al. Successful application of extracorporeal membrane oxygenation and intra-aortic balloon counterpulsation as lifesaving therapy for a patient with amniotic fluid embolism. Am J Obstet Gynecol 2000; 183:496-497.
87. Esposito RA, Grossi EA, Coppa G, et al. Successful treatment of postpartum shock caused by amniotic fluid embolism with cardiopulmonary bypass and pulmonary artery thromboembolectomy. Am J Obstet Gynecol 1990; 163:572-574.
88. Weksler N, Ovadia L, Stav A, et al. Continuous arteriovenous hemofiltration in the treatment of amniotic fluid embolism. Int J Obstet Anesth 1994; 3:92-96.
89. Dodgson J, Martin J, Boswell J, et al. Probable amniotic fluid embolism precipitated by amniocentesis and treated by exchange transfusion. Br Med J (Clin Res Ed) 1987; 294:1322-1323.
90. Ogihara T, Morimoto K, Kaneko Y. Continuous hemodiafiltration for potential amniotic fluid embolism: dramatic responses observed during a 10-year period report of three cases. Ther Apher Dial 2012; 16:195-197.